Skip to main content

Table 2 Meta-analysis with a fixed-effect model for pooling studies on 203 patients on progression-free survival (PFS)

From: Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment

Study name

Statistics for each study

 
 

Meana

Standard error

Variance

Lower limit

Upper limit

Z value

P value

Totalb

Rautiola, 2013

11.0

2.222

4.937

6.65

15.36

4.951

0.000

14

Matrana, 2013

3.50

1.203

1.447

1.14

5.86

2.910

0.004

17

Sanchez, 2013

13.00

1.961

3.847

9.16

16.84

6.628

0.000

32

Hainsworth, 2013

7.50

0.973

0.946

5.59

9.41

7.711

0.000

55

Xie, 2015

5.60

0.578

0.334

4.47

6.73

9.684

0.000

85

pooled synthesis

6.29

0.438

0.192

5.43

7.15

14.339

0.000

203

 

I2 = 83.7 %

 
  1. Random-effects model estimates a median PFS of 7.6 months (95 % CI, 5.0–10.1)
  2. aPFS in months; bnumber of patients in each study; Data in bold-type are the result of data synthesis
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us